Results at 2 years of a phase IIb extension study of the exon-skipping drug eteplirsen in patients with DMD

被引：1

作者：

Mendell, J. R. ^{[1
]}

Rodino-Klapac, L. ^{[1
]}

Sahenk, Z. ^{[1
]}

Roush, K. ^{[1
]}

Bird, L. ^{[1
]}

Lowes, L. P. ^{[1
]}

Alfano, L. ^{[1
]}

Gomez, A. M. ^{[1
]}

Lewis, S. ^{[1
]}

Malik, V. ^{[1
]}

Shontz, K. ^{[1
]}

Flanigan, K. M. ^{[1
]}

Kean, J. R. ^{[1
]}

Allen, H. D. ^{[1
]}

Shilling, C. ^{[1
]}

Sazani, P. ^{[2
]}

Saoud, J. ^{[2
]}

Kaye, E. M. ^{[2
]}

机构：

[1] Nationwide Childrens Hosp, Columbus, OH USA

[2] Sarepta Therapeut, Cambridge, MA USA

来源：

NEUROMUSCULAR DISORDERS | 2013年 / 23卷 / 9-10期

关键词：

D O I：

10.1016/j.nmd.2013.06.581

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：804 / 805

页数：2

共 50 条

[21] Final Outcomes of the Teriflunomide Phase 2 Extension Study: 13 Years of Efficacy and Safety Results
Kremenchutzky, Marcelo
Freedman, Mark
Bar-Or, Amit
Purvis, Annie
Benamor, Myriam
Truffinet, Philippe
O'Connor, Paul
NEUROLOGY, 2016, 86
[22] Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.
Krebs, Matthew
Spira, Alexander I.
Cho, Byoung Chul
Besse, Benjamin
Goldman, Jonathan W.
Janne, Pasi A.
Ma, Zhiyong
Mansfield, Aaron Scott
Minchom, Anna Rachel
Ou, Sai-Hong Ignatius
Salgia, Ravi
Wang, Zhijie
Perez, Casilda Llacer
Gao, Grace
Curtin, Joshua C.
Roshak, Amy
Schnepp, Robert W.
Thayu, Meena
Knoblauch, Roland
Lee, Chee Khoon
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[23] Exon-skipping as a therapeutic approach for treatment of retina degeneration in patients carrying the intronic USH2A c.7595-2144A>G mutation
Slijkerman, Ralph
Vache, Christel
Dona, Margo
Garcia-Garcia, Gema
Claustres, Mireille
Hetterschijt, Lisette
Peters, Theo
Collin, Rob
Kremer, Hannie
Roux, Anne Francoise
van Wyk, Erwin
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
[24] Casimersen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping: Interim Results from the Phase 3 ESSENCE Trial
Iannoccone, S.
Phan, H.
Straub, V
Muntoni, F.
Koenig, E.
Malhotra, J.
Darton, E.
Han, B.
Mercuri, E.
ANNALS OF NEUROLOGY, 2021, 90 : S155 - S155
[25] Casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: interim results from the Phase 3 ESSENCE trial
Iannaccone, S.
Phan, H.
Straub, V.
Muntoni, F.
Koenig, E.
Malhotra, J.
Han, B.
Darton, E.
Mercuri, E.
NEUROMUSCULAR DISORDERS, 2021, 31 : S94 - S95
[26] Casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: Interim results from the Phase 3 ESSENCE trial
Iannaccone, S.
Phan, H.
Straub, V.
Muntoni, F.
Wolf, D.
Malhotra, J.
Chu, R.
Darton, E.
Mercuri, E.
NEUROMUSCULAR DISORDERS, 2022, 32 : S102 - S102
[27] Casimersen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping: Interim Results from the Phase 3 ESSENCE Trial
Iannaccone, S.
Phan, H.
Straub, V
Muntoni, F.
Wolf, D.
Malhotra, J.
Chu, R.
Darton, E.
Brandl, K.
Mercuri, E.
ANNALS OF NEUROLOGY, 2022, 92 : S152 - S152
[28] Phase 1/2 trial evaluating AOC 1044 in healthy volunteers and participants with DMD mutations amenable to exon 44 Skipping: EXPLORE44 Trial Design
Stahl, M.
Ackermann, E.
Chen, C.
Zhu, Y.
Cho, H.
Hughes, S.
DiTrapani, K.
Laverty, C.
McDonald, C.
NEUROMUSCULAR DISORDERS, 2023, 33 : S69 - S69
[29] Safety Profile in SLE Patients Treated with Atacicept in a Phase IIb Study (ADDRESS II) and Its Extension Study
Merrill, Joan T.
Wallace, Daniel J.
Vazquez-Mateo, Cristina
Kao, Amy H.
Fleuranceau-Morel, Patricia
Chang, Peter
Isenberg, David A.
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[30] EIGHT YEARS OF CONTINUED ODANACATIB THERAPY FOR POSTMENOPAUSAL WOMEN WITH LOW BONE MINERAL DENSITY: RESULTS FROM AN OPEN-LABEL EXTENSION TO A PHASE IIB STUDY
Rizzoli, R.
Rodriguez Portales, J. A.
Benhamou, C. L.
Halse, J.
Miller, P. D.
Reid, I.
Dasilva, C.
Kroon, R.
Leung, A.
Gurner, D.
OSTEOPOROSIS INTERNATIONAL, 2014, 25 : S123 - S124

← 1 2 3 4 5 →